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Background: Magnesium sulphate is currently recommended for neuroprotection of preterm infants for women at
risk of preterm birth at less than 30 weeks’ gestation, based on high quality evidence of benefit. However there
remains uncertainty as to whether these benefits apply at higher gestational ages.
The aim of this randomised controlled trial is to assess whether giving magnesium sulphate compared with
placebo to women immediately prior to preterm birth between 30 and 34 weeks’ gestation reduces the risk of
death or cerebral palsy in their children at two years’ corrected age.
Methods/design
Design: Randomised, multicentre, placebo controlled trial.
Inclusion criteria: Women, giving informed consent, at risk of preterm birth between 30 to 34 weeks’ gestation,
where birth is planned or definitely expected within 24 hours, with a singleton or twin pregnancy and no
contraindications to the use of magnesium sulphate.
Trial entry & randomisation: Eligible women will be randomly allocated to receive either magnesium sulphate or
placebo.
Treatment groups: Women in the magnesium sulphate group will be administered 50 ml of a 100 ml infusion bag
containing 8 g magnesium sulphate heptahydrate [16 mmol magnesium ions]. Women in the placebo group will
be administered 50 ml of a 100 ml infusion bag containing isotonic sodium chloride solution (0.9%). Both
treatments will be administered through a dedicated IV infusion line over 30 minutes.
Primary study outcome: Death or cerebral palsy measured in children at two years’ corrected age.
Sample size: 1676 children are required to detect a decrease in the combined outcome of death or cerebral palsy,
from 9.6% with placebo to 5.4% with magnesium sulphate (two-sided alpha 0.05, 80% power, 5% loss to follow up,
design effect 1.2).
Discussion: Given the magnitude of the protective effect in the systematic review, the ongoing uncertainty about
benefits at later gestational ages, the serious health and cost consequences of cerebral palsy for the child, family
and society, a trial of magnesium sulphate for women at risk of preterm birth between 30 to 34 weeks’ gestation is
both important and relevant for clinical practice globally.
Trial registration: Australian New Zealand Clinical Trials Registry - ACTRN12611000491965
Keywords: Magnesium sulphate, Neuroprotection, Preterm birth, Randomised controlled trial, Cerebral palsy* Correspondence: caroline.crowther@adelaide.edu.au
1Australian Research Centre for Health of Women and Babies (ARCH), The
Robinson Institute, The University of Adelaide, Adelaide, Australia
2Liggins Institute, The University of Auckland, Auckland, New Zealand
Full list of author information is available at the end of the article
© 2013 Crowther et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the oral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Crowther et al. BMC Pregnancy and Childbirth 2013, 13:91 Page 2 of 9
http://www.biomedcentral.com/1471-2393/13/91Background
Babies born preterm have a higher chance of dying in
the first few weeks of life than those born at term [1].
Babies who survive have a greater risk of neurologic
impairments, such as cerebral palsy, blindness, deafness,
or cognitive dysfunction, and a greater risk of substantial
disability as a result of these neurologic impairments
[2-4]. The social and economic long-term costs are
considerable [5].
Cerebral palsy is a term which includes a number of
different diseases or conditions that can arise at any time
during brain development. It involves a disorder of
movement or posture, or both, and a disorder of motor
function that is permanent but may change over time
[6]. The cerebral palsies remain the most frequent
cause of severe motor disability in childhood with a
background prevalence of two per thousand live births
[6]. Most affected children (92%) survive to 20 years
or later, yielding a substantial burden of illness into
adulthood [7].
Very preterm birth (less than 34 weeks) is the principal
risk factor for cerebral palsy [8,9], responsible for 17%
to 32% of all cases of cerebral palsy. The latest
Australian Cerebral Palsy Register Report (2009)
shows that approximately 45% of all cases of cerebral
palsy are associated with preterm birth [10]. Whilst
the highest risks are for extremely preterm infants
[3], babies born between 30 and 33 completed weeks’
gestation still have significant risks [11] with the risk
of cerebral palsy being up to eight times more likely
than babies born at term [4]. Moderate prematurity is
responsible for as many cases of cerebral palsy as extreme
prematurity [10].
At present there is no cure for cerebral palsy, which
makes effective preventative interventions of paramount
importance. Prevention of cerebral palsy has been
identified by consumers, clinicians and researchers as
a top priority for research by the Australian Cerebral
Palsy Institute [12]. To reduce the impact of cerebral
palsy from preterm birth, efforts must be focused on
primary prevention.Observational studies on the effect of antenatal
magnesium sulphate on neurodevelopment
A landmark case–control study 15 years ago described
the association of exposure to antenatal magnesium
sulphate with a dramatic reduction in the risk of cerebral
palsy (odds ratio (OR) 0.14; 95% confidence interval (CI)
0.05 to 0.51) [13]. Other observational studies support
a reduction in cerebral palsy in preterm babies after
antenatal magnesium sulphate [14-16] and some a
reduction in the risk of intraventricular hemorrhage
(IVH) [16,17] and perinatal mortality [18]. However, notall studies report benefit for antenatal magnesium sulphate
on the risk of IVH [19-21], cerebral palsy [20,22,23] or
perinatal mortality [19].Biological plausibility for use of magnesium sulphate for
fetal and infant neuroprotection
In humans, magnesium is essential for key cellular
processes, including glycolysis, oxidative phosphorylation,
protein synthesis, DNA and RNA aggregation and
maintenance of plasma membrane integrity [24,25].
Magnesium favourably affects mechanisms implicated in
cell death by decreasing proinflammatory cytokines or free
radicals produced during hypoxic-ischaemic reperfusion
and inflammatory diseases of pregnancy [26,27]. Magne-
sium prevents excitotoxic calcium-induced injury [28], by
a non-competitive voltage-dependent inhibition of the
N-methyl-D-aspartate receptor to glutamate reducing
calcium entry into the cell [29]. The fetal and neonatal
brain seems more susceptible to glutamate damage.
Consequently, blocking glutamate receptors through
agents such as magnesium sulphate may reduce the risk
of injury in the perinatal period. Magnesium has some
beneficial haemodynamic effects including stabilising
blood pressure during the first two days of life in preterm
neonates [30], and may increase cerebral blood flow by
reducing constriction of the cerebral arteries [31].
Transplacental transfer of magnesium is rapid with
magnesium concentrations increased in fetal serum within
one hour of maternal intravenous administration [32].Maternal and neonatal adverse effects and side effects of
magnesium sulphate
The best available evidence about potential maternal
harms from antenatal magnesium sulphate administration
comes from the four Cochrane reviews that compare
magnesium sulphate with placebo or no treatment
[33-36]. Magnesium sulphate, by its peripheral vasodilator
effects when infused intravenously, produces a sensation
of warmth and flushing. Reported maternal side-effects,
related to dosage and speed of infusion, include nausea,
vomiting, headache and palpitations. Hypotension and
respiratory depression are more severe recognised risks.
Magnesium sulphate acts as a neuromuscular blocking
agent that causes abolition of tendon reflexes [37].
Magnesium could aggravate the cardiovascular or neuro-
muscular side-effects of other drugs such as betamimetics,
calcium-channel blockers and gentamicin [38,39]. Infusion
to concentrations above the recommended therapeutic
range can have life threatening consequences for the
women that include respiratory arrest and cardiac arrest
leading to death [40]. For the neonate, hypermagnesaemia
can lead to hyporeflexia, poor sucking, and, rarely, respira-
tory depression needing assisted ventilation [41,42].
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burden of being born preterm
Systematic review of randomized trials of magnesium
sulphate for neonatal neuroprotection
The updated Cochrane systematic review to assess the
use of antenatal magnesium sulphate for women at risk
of preterm birth [33] included four trials (4446 babies)
where magnesium sulphate had been given specifically
for neuroprotection of the fetus; two from the US; the
MagNet Trial [43] and the BEAM Trial [44], one from
Australia and New Zealand; the ACTOMgSO4 Trial
[45], one from France; the PreMag Trial [46]. There was
diversity in the inclusion and exclusion criteria for the
four included trials with wide variation in gestational
age, reasons women were at risk of preterm birth and
time of treatment prior to expected preterm birth [33].
All trials used intravenous magnesium sulphate although
the dose used, whether a maintenance infusion was
given and whether treatment could be repeated varied
between trials.
Results of the meta-analysis of the Cochrane systematic
review
The combined outcome of death or cerebral palsy or
cerebral palsy alone showed significant reductions where
women who were at risk of preterm birth were given
magnesium sulphate antenatally with the intent of
providing neuroprotection (Table 1). The review showed
that 63 babies (95% CI 44 to 155) need to be treated
with magnesium sulphate for one baby to avoid cerebral
palsy. The corresponding number needed to treat to
benefit (NNTB) for combined death or cerebral palsy
was 42 babies, 95% CI 24 to 346.
Is there clinical evidence for the role of antenatal
magnesium sulphate for neuroprotection of the fetus,
infant and child prior to preterm birth at 30 to 34 weeks
gestation?
The Australian and New Zealand Bi-national Clinical
Practice Guidelines on the use of antenatal magnesium
sulphate prior to preterm birth for neuroprotection of
the fetus, infant and child summarise the evidence
available from the four individual neuroprotective intent
trials within the Doyle 2009 Cochrane Review [33] thatTable 1 Magnesium sulphate vs placebo/no treatment: prima
Primary outcomes RR
Death or cerebral palsy 0.
Death (fetal and later) 0.
Cerebral palsy 0.
Any neurological impairment 1.
Death or substantial gross motor dysfunction 0.
*Significantly in favour of magnesium sulphate.consider gestational age at trial entry and effect of antenatal
magnesium sulphate [47]. All women in the four included
trials were given magnesium sulphate before 34 weeks’
gestation. In Rouse 2008, all women were less than
32 weeks at trial entry with the majority (68% of trial
participants) less than 30 weeks gestation [44]. Subgroup
analyses for women at different gestational ages were
possible for women with a gestational age of less than
34 weeks, less than 33 weeks, less than 32 weeks and
less than 30 weeks. However there was only one trial
within each subgroup available for analysis and the results
are inconclusive due to small sample sizes (Table 2).
Summary of CPG evidence statement judgements for
gestational age subgroup
The subgroup analyses are from trials with low risk of
bias, with results between trials fairly consistent. While
the evidence is applicable to the Australian and New
Zealand context, generalisability was reduced as the
majority of the women (87%) in the largest trial [44] had
PPROM and so represent a limited subset of women at
risk of preterm birth. Overall clinical impact was judged
to be very large (Table 2) but any differences in death
and cerebral palsy by gestational age are unclear at
present. To minimise the number of women exposed,
the Australian and New Zealand clinic practice guideline
panel felt it would be prudent to restrict magnesium
sulphate administration to the subgroup containing the
lowest gestational age (less than 30 weeks).
Recommendations made by the Australian and New
Zealand Bi-National CPG panel for use of antenatal
magnesium sulphate
The main clinical recommendation is to use magnesium
sulphate for neuroprotection of the fetus, infant and
child “in women at risk of early preterm (gestational age
is less than 30 weeks), imminent birth (when early
preterm birth is planned or definitely expected within
24 hours)” [47].
In recognition of the need for further research, the
guideline panel specifically recommended that further
randomised trials were needed, comparing antenatal
magnesium sulphate with placebo when given to women
at risk of preterm birth at 30 weeks’ gestation or more,ry outcomes [33]
, 95% CI Number of trials; participants
85, 0.74 to 0.98* four trials; 4446 infants
95, 0.80 to 1.12 four trials; 4446 infants
71, 0.55 to 0.91* four trials; 4446 infants
03, 0.87 to 1.21 one trial; 1255 infants
84, 0.71 to 1.00 three trials; 4387 infants
Table 2 Results of primary outcomes by gestational age subgroup [33]
Trial N Eligible
(GA wks)
DEATH or CP CP DEATH
RR, 95% CI RR, 95% CI RR, 95% CI
MagNetǂ [43] 59 >24 to <34 4.83, 0.60 to 38.90 6.77, 0.37 to 125.65 1.93, 0.19 to 20.18
Marret[46] 688 viable to <33 0.80, 0.58 to 1.10 0.70, 0.41 to 1.19 0.85, 0.55 to 1.32
Rouse[44] 2444 24 to <32 0.90, 0.73 to 1.10 0.59, 0.40 to 0.85* 1.13, 0.87 to 1.48
Crowther[45] 1255 <30 0.82, 0.66 to 1.02 0.85, 0.55 to 1.31 0.81, 0.62 to 1.05
Overall 4446 viable to <34 0.85, 0.75 to 0.98* 0.71, 0.55 to 0.91* 0.95, 0.80 to 1.12
ǂNeuroprotective arm; CP cerebral palsy; GA gestational age; * statistically significant.
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and cerebral palsy [47].
Preventative strategies that may reduce the risk of
cerebral palsy need appropriate evaluation prior to
introduction into clinical practice. Given the magnitude
of the protective effect in the systematic review, the
ongoing uncertainty about benefits at later gestational
ages, the serious health and cost consequences of this
condition for the child, family and society a trial of
magnesium sulphate for women at risk of preterm birth
between 30 to 34 weeks’ gestation is both justifiable
and needed.
Aims and objectives of this trial
The aim of this randomised controlled trial is to assess
whether giving magnesium sulphate compared with
placebo to women immediately prior to preterm birth
between 30 and 34 weeks’ gestation reduces the risk of
death or cerebral palsy in their children at two years’
corrected age.
Hypotheses
The primary hypothesis is that antenatal magnesium
sulphate compared with placebo given to women at risk
of preterm birth between 30 and 34 weeks’ gestation
when birth is imminent (defined as planned or definitely
expected in the next 24 hours) reduces the risk of death or
cerebral palsy in their children at two years’ corrected age.
The secondary hypotheses are that antenatal magnesium
sulphate compared with placebo given to women at risk
of preterm birth between 30 and 34 weeks’ gestation when
birth is imminent (defined as planned or definitely
expected in the next 24 hours) above has benefits relating
to the infant/child: including individual components of
the primary outcome (mortality and cerebral palsy), and
neonatal and childhood morbidity (including IVH and the
other neurosensory disabilities at two years’ corrected age
of blindness, deafness or developmental delay). At the
same time, it is hypothesized that the intervention does
not harm the mother: no clinically important effect on
mode of birth or maternal morbidity as measured by risk
of serious adverse cardiovascular effects of the infusion,
side effects of the infusion and postpartum haemorrhage.Methods/design
Ethics statement
Ethics approval was granted by the Children’s Youth
and Women’s Health Services Human Research Ethics
Committee at the Women’s and Children’s Hospital
(REC2303/8/13) and by the local institutional review
boards for each centre.
Study design
Randomised, multicentre, placebo controlled trial.
Inclusion criteria
Women are eligible for the trial if they are at risk of
preterm birth between 30 to 34 weeks’ gestation where
birth is planned or definitely expected within 24 hours,
have a singleton or twin pregnancy, no contraindications
to the use of antenatal magnesium sulphate (respiratory
depression, hypotension, renal failure, myasthenia gravis)
and give informed, written consent.
Exclusion criteria
Women are not eligible if they have a higher-order
multiple pregnancy, have received antenatal magnesium
sulphate in the current pregnancy or if magnesium
sulphate therapy is considered essential for the treatment
of pre-eclampsia [36].
Trial entry
Eligible women are given the trial information sheet,
counselled by a member of the research team and
encouraged to discuss the study with family before
consent is sought.
Study groups
Once all entry details are given and eligibility is confirmed,
the woman is randomised by contacting the central
telephone randomisation service at the University of
Adelaide. Assignment to one of two study groups: either
the magnesium sulphate group or the placebo group will
be stratified for collaborating centre, gestational age (30 to
31 completed weeks; 32–33 completed weeks’ gestation),
and number of fetuses (1 or 2). A Study Number is
allocated to the woman corresponding to a treatment
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infusion bag.
Magnesium sulphate study group
Women randomised to the magnesium sulphate study
group are administered 50 ml of a 100 ml infusion
bag containing 8 g magnesium sulphate heptahydrate
[16 mmol magnesium ions] through a dedicated intravenous
infusion line over 30 minutes.
Placebo study group
Women randomised to the placebo study group are
administered 50 ml of a 100 ml infusion bag containing
isotonic sodium chloride solution (0.9%) through a
dedicated intravenous infusion line over 30 minutes.
Both study groups
The woman’s pulse, blood pressure and respiratory rate are
assessed and recorded before the infusion is commenced,
fifteen minutes after the infusion has started and at the end
of the infusion. Any other monitoring as per the individual
obstetric unit protocols for intravenous administration of
magnesium sulphate is followed. Magnesium toxicity is
unlikely with the regimen recommended in this protocol
and serum magnesium concentrations do not need to
be routinely measured. There is a potential theoretical
interaction between magnesium sulphate and nifedipine
of hypotension and neuromuscular blockade effects, al-
though this is seldom reported in clinical practice [38,39].
The trial treatment infusion should be stopped if the
respiratory rate decreases more than four breaths per
minute below baseline, or is less than 12 breaths per
minute; or diastolic blood pressure decreases more than
15 mmHg below baseline level [47]. The infusion may be
continued when the respiratory rate or the blood pressure
return to the baseline levels. Should hypotension or
respiratory depression occur, prompt medical review
is recommended. If there is clinical concern over
respiratory depression calcium gluconate (1 g [10 ml of
10% solution] can be given slowly via the intravenous
route over 10 minutes). Resuscitation and ventilatory
support should be immediately available, if needed, during
administration of the study medication. At the end of the
trial treatment infusion, the section on maternal side
effects should be completed on the Treatment form.
Care during labour and the postnatal stay will be
managed by the obstetric team caring for the woman.
Care of the neonate is the responsibility of the attending
neonatologist.
Follow up after birth until the time of primary discharge
for both groups
The pregnancy and labour data will be extracted from
case notes by the masked research assistant at thecollaborating hospitals. The postnatal and neonatal data
will be collected similarly after discharge of the mother
and baby from hospital.
Longer term follow up
Women enrolled in the trial will give consent for follow-up
of their children from birth until two years’ corrected age
at the time of the initial, prenatal recruitment. Mothers of
all babies discharged home alive will be contacted by a
member of the study team from the coordinating centre
at The University of Adelaide by mail soon after hospital
discharge and then again when their baby is six, 12 and
18 months corrected age. Mothers will be provided with a
reply paid envelope and asked to confirm their current
contact details by mail. At each of these times, a member
of the study team at the coordinating centre will contact
the parents by telephone if a response has not been
received in the mail.
Two years assessments
All surviving children will be formally assessed at two
years of age, corrected for prematurity, by a developmental
paediatrician and psychologist or other assessor trained to
administer the Bayley Scales. All assessors will remain
blinded to treatment group assignment. Assessments will
be made of health, neurodevelopment, behaviour, growth
and blood pressure. This format of assessment has been
used in our previous trials [45,48]. Although cerebral palsy
may not remain a stable diagnosis before five years of age
[49], a diagnosis of severe cerebral palsy (defined below) at
two years of age is unlikely to change subsequently [50].
Gross Motor Function: The paediatric assessment will
include a neurological examination to diagnose cerebral
palsy (abnormality of tone with motor dysfunction) and
other disability outcomes according to previously reported
criteria [51]. Gross Motor Function will be assessed using
the Gross Motor Function Classification System (GMFCS)
level 0 to 5 [52].
Psychological Assessments: The psychological assessment
will include the cognitive, motor and language scales
of the Third Edition of the Bayley Scales of Infant
Development (BSID-III) [53]. This is well-standardised
with demonstrated validity and reliability. Psychological
test scores will be recorded as standardised scores [derived
from raw test scores - mean/standard deviation (SD)].
Children with severe developmental delay who are unable
to complete the psychological assessment will be given a
standardised score of 4 SD below the mean.
Behaviour: The child's caregiver will be asked to
complete the child behaviour checklist [54].
General Health, Health Resource Utilisation, Blood
Pressure and Body Size: A general history and physical
examination will determine the presence of any significant
chronic illness, and data regarding hospital readmissions
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hospital or doctor. Children will be considered blind if
visual acuity in both eyes is worse than 6/60. Children will
be considered deaf if their hearing loss is sufficient to
require hearing aid(s), or worse.
Blood pressure will be measured and converted to
Z-scores relative to American data for blood pressure for
age, height and gender in childhood [55].
Questionnaires will be completed by the child's caregiver
about any respiratory morbidity, history of illness or injury
and use of health services since primary hospitalisation
(Parent/Caregiver Questionnaire).
The child's height, weight, and head circumference will
be measured in the standard way, and values for the
relevant centile, percent of median, and standard deviation
scores (Z scores) specific for age and gender will be
computed from the British Growth Reference [56].Categorisation of neurosensory disability
Children will be considered to have a neurosensory
impairment if they have cerebral palsy, GMFCS level
1 to 5, blindness, deafness any of the Bayley Scale
scores more than 1 SD below the mean (<−1SD). The
neurosensory disabilities imposed by the various neuro-
sensory impairments will be classified as severe, moderate
or mild [51] (Table 3).Primary study endpoints
The primary study endpoint measured in the children at
two years’ corrected age is the combined incidence of death
or cerebral palsy defined as stillbirths, death of live born
infant before hospital discharge or death after hospital
discharge before two years’ corrected age; or any cerebral
palsy [abnormality of tone with motor dysfunction].Table 3 Neurosensory Disability Classifications [51]
Severe Disability Any severe cerebral palsy (child
non-ambulant and likely to remain
so; GMFCS level 4 or 5), severe
developmental delay (standardised
score <−3 SD) or blindness.
Moderate Disability Moderate cerebral palsy (child
non-ambulant at 2 years of age but
who is likely to ambulate
subsequently; GMFCS level 2 or 3),
or deafness, or moderate
developmental delay (standardised
score from −3 SD to <−2 SD).
Mild Disability Mild cerebral palsy (child walking at
2 years of age with only minimal
limitation of movement (GMFCS
level 1), or suspect developmental
delay (standardised score from
−2 SD to <−1 SD).
No Neurosensory Disability Children without any neurosensory
impairment.Secondary study endpoints
For the infant
 Health outcomes considered to be important
measures of mortality and morbidity prior to
primary hospital discharge; (defined as stillbirth and
death of liveborn infant before hospital discharge;
IVH, severe IVH, cystic PVL, neonatal
encephalopathy, neonatal convulsions, proven
necrotising enterocolitis, retinopathy of prematurity
needing treatment, patent ductus arteriosus needing
treatment, respiratory distress syndrome, severity of
any neonatal lung disease, chronic lung disease
(oxygen dependent at 36 weeks post-menstrual age
or 28 days of life if born after 32 weeks gestation),
use of respiratory support, airleak requiring
drainage, confirmed infection within the first
48 hours, infection after the first 48 hours, body size
at birth (weight, length, head circumference) and at
discharge home).
 Composite serious health outcome (defined as
stillbirth and death of liveborn infant before hospital
discharge severe respiratory disease, severe
intraventricular haemorrhage (grade 3 & 4); chronic
lung disease (oxygen dependent at 36 weeks post-
menstrual age or 28 days of life if born after 32 weeks
gestation); proven necrotising enterocolitis; severe
retinopathy of prematurity (Stage 3 or worse in the
better eye); cystic periventricular leukomalacia).
For the child
Key health outcomes assessed at two years’ corrected age:
 Individual components of the primary outcome
including severity of cerebral palsy (defined as death;
cerebral palsy).
 Death or any neurosensory disability (death defined
as stillbirth, death of live born infant before hospital
discharge or death after hospital discharge; and any
neurosensory disabilities that includes the
neurosensory impairments of cerebral palsy,
[GMFCS level 1 to 5], blindness [corrected visual
acuity worse than 6/60 in the better eye], deafness
[hearing loss requiring amplification or worse], and
any developmental delay defined as standardised
score more than 1 SD below the mean (< −1SD).
 Death or major neurosensory disability. Major
neurosensory disability includes severe and moderate
disability (defined as any of: legal blindness,
sensorineural deafness requiring hearing aids;
moderate or severe cerebral palsy [GMFCS level 2
to 5] or developmental delay/intellectual impairment
[standardised score more than two SD below
the mean].
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services since primary hospitalisation), childhood
respiratory morbidity, blood pressure (Z scores and
proportions in hypertensive ranges), behaviour as
assessed by the Child Behaviour Checklist [54] and
body size.
For the mother
 Maternal serious adverse cardiovascular and/or
respiratory outcome of the infusion (defined as
maternal death, cardiac arrest, respiratory arrest).
 Maternal side effects of the infusion (including
nausea; vomiting; flushing, infusion arm discomfort;
mouth dryness; sweating; dizziness; blurred vision;
respiratory rate decreased > four breaths per minute
below baseline or <12 breaths per minute; blood
pressure decreased > 15 mmHg below baseline level;
whether the infusion is discontinued because of
side effects).
 Incidence of postpartum haemorrhage, estimated
blood loss at birth 500 ml or more; and major
postpartum haemorrhage, estimated blood loss
1500 ml or more; mode of birth.
Sample size
The rate of our primary outcome of death or cerebral
palsy at two years’ corrected age in an Australian/New
Zealand population between 30 to 34 weeks’ gestation is
estimated to be 9.6%, using a predicted mortality rate up
to 2 years of age of 4.4% (excluding lethal anomalies)
[57] and a predicted rate of cerebral palsy in survivors of
5.2% [46,48].
A trial of 1676 children (838 per group), allowing for a
design effect of 1.2 for clustering of babies within
mothers and a 5% loss to follow up, with an absolute risk
difference of 4.2% [45,46,48] will have 80% power to
detect a statistically significant difference at an alpha
level of 0.05 (two-tailed) of a decrease in the combined
outcome of death or cerebral palsy from 9.6% to 5.4%
with magnesium sulphate compared with placebo.
Analysis and reporting of results
Data will be analysed by a statistician independent of the
clinical investigators. Potential confounding variables will
comprise socio-demographic variables, such as ethnicity,
language spoken at home, family structure, mother’s
marital status, social class, and mother’s and father’s
education, as well as gender of the baby. Comparisons will
be made between treatment groups for the primary and
secondary endpoints using an intention to treat approach.
Analyses will make adjustments for the stratification
variables and for important baseline predictors including
gestational age at birth, and reasons for risk of pretermbirth. Log binomial regression and linear regression will be
used to examine dichotomous and continuous outcomes
respectively with results presented as relative risks or
differences in means along with 95% confidence intervals.
Adjustment till be made for clustering due to multiple
births for infant outcomes using generalized estimating
equations. P-values <0.05 will be considered statistically
significant.
Discussion
The MAGENTA randomised trial assessing the use of
antenatal magnesium sulphate in women at risk of preterm
birth between 30 to 34 weeks’ gestation for neuroprotection
of their infants is important and relevant for clinical
practice globally.
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